ReviewBiological psychiatry2011
A roadmap for the development and validation of event-related potential biomarkers in schizophrenia research.
Review in Biological psychiatry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
91 citing papers in PubMed, 1 synthesis or guideline pooled it, 192 citations in OpenAlex.
- Evaluation of Event-Related Potentials in Somatic Diseases - Systematic Review.Applied psychophysiology and biofeedback · 2024Pooled it
- GABA Deficits Enhance the Psychotomimetic Effects of Δ9-THC.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2015Trial
- Memantine effects on verbal memory in fragile X-associated tremor/ataxia syndrome (FXTAS): a double-blind brain potential study.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2014Trial
- Dose-related modulation of event-related potentials to novel and target stimuli by intravenous Δ⁹-THC in humans.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2012Trial
- Inclusive mobile brain-body imaging achieves equivalent EEG data quality across racial groups.PLOS digital health · 2026Article
- Uncovering putative neural mechanisms of neurotherapeutic impacts on EEG using the Human Neocortical Neurosolver.bioRxiv : the preprint server for biology · 2026Article
- Sex differences in event-related potentials and their clinical predictive value in first-episode antipsychotic-naïve schizophrenia.European archives of psychiatry and clinical neuroscience · 2026Article
- Event-related potential correlates of visual processing across obsessive-compulsive and anxiety spectrum disorders: A scoping review.Neuroscience and biobehavioral reviews · 2025Article
- Translating neurophysiological biomarkers into clinical tools: A psychometric blueprint illustrated with the error-related negativity.The American psychologist · 2025Review
- Superconducting Quantum Magnetometers for Brain Investigations.Sensors (Basel, Switzerland) · 2025Review
- The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures.Schizophrenia (Heidelberg, Germany) · 2025Article
- Prefrontal Oscillatory Slowing in Early-Course Schizophrenia Is Associated With Worse Cognitive Performance and Negative Symptoms: A Transcranial Magnetic Stimulation-Electroencephalography Study.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2025Article
- Peak Alpha Frequency in Schizophrenia, Bipolar Disorder, and Healthy Volunteers: Associations With Visual Information Processing and Cognition.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2024Article
- How to Solve Clinical Challenges in Mood Disorders; Machine Learning Approaches Using Electrophysiological Markers.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2024Review
- Applications of OPM-MEG for translational neuroscience: a perspective.Translational psychiatry · 2024Review
- An ERP Study of Face Processing in Schizophrenia, Bipolar Disorder, and Socially Isolated Individuals from the Community.Clinical EEG and neuroscience · 2024Article
- P300 in schizophrenia: Then and now.Biological psychology · 2024Review
- The Use of Event-Related Potentials in the Study of Schizophrenia: An Overview.Advances in neurobiology · 2024Review
- Advanced Methodology for Neurophysiological Analysis and Biomarker Development: Time-Frequency and Source-Localization Approaches.Advances in neurobiology · 2024Review
- Maintaining Task Performance Levels Under Cognitive Load While Walking Requires Widespread Reallocation of Neural Resources.Neuroscience · 2023Article
31 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
7 authors at 7 institutions in 2 countries.
Funding
Abstract
New efforts to develop treatments for cognitive dysfunction in mental illnesses would benefit enormously from biomarkers that provide sensitive and reliable measures of the neural events underlying cognition. Here, we evaluate the promise of event-related potentials (ERPs) as biomarkers of cognitive dysfunction in schizophrenia. We conclude that ERPs have several desirable properties: (1) they provide a direct measure of electrical activity during neurotransmission; (2) their high temporal resolutions make it possible to measure neural synchrony and oscillations; (3) they are relatively inexpensive and convenient to record; (4) animal models are readily available for several ERP components; (5) decades of research has established the sensitivity and reliability of ERP measures in psychiatric illnesses; and 6) feasibility of large N (>500) multisite studies has been demonstrated for key measures. Consequently, ERPs may be useful for identifying endophenotypes and defining treatment targets, for evaluating new compounds in animals and in humans, and for identifying individuals who are good candidates for early interventions or for specific treatments. However, several challenges must be overcome before ERPs gain widespread use as biomarkers in schizophrenia research, and we make several recommendations for the research that is necessary to develop and validate ERP-based biomarkers that can have a real impact on treatment development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.